-
公开(公告)号:US20230285281A1
公开(公告)日:2023-09-14
申请号:US18081229
申请日:2022-12-14
Applicant: OCULAR THERAPEUTIX, INC.
Inventor: Charles D. Blizzard , Ankita Desai , Arthur Driscoll , Michael Goldstein
IPC: A61K9/00 , A61K9/14 , A61K31/5575 , C08L67/04 , A61K47/69 , A61P27/06 , A61K31/216 , A61K47/10
CPC classification number: A61K9/0051 , A61K9/146 , A61K31/5575 , C08L67/04 , A61K47/6903 , A61K47/6937 , A61P27/06 , A61K9/0048 , A61K31/216 , A61K47/10 , C08L2201/06 , C08L2312/00
Abstract: The present invention relates to the treatment of ocular diseases in a human subject. In particular, the invention relates to an intracameral administration of a sustained release biodegradable intracameral implant.
-
公开(公告)号:US11534396B2
公开(公告)日:2022-12-27
申请号:US17744189
申请日:2022-05-13
Applicant: Ocular Therapeutix, Inc.
Inventor: Charles D. Blizzard , Arthur Driscoll , Rami El-Hayek , Michael Goldstein , Joseph Iacona , Peter Jarrett , Timothy S. Jarrett , Erica Kahn , Zachary Lattrell
IPC: A61K9/00 , A61K9/06 , A61K31/4439 , A61P27/02 , A61K31/4427 , A61K47/34 , A61K45/06
Abstract: This invention relates to methods of treatment with a sustained release biodegradable ocular implant containing a tyrosine inhibitor dispersed in a hydrogel.
-
公开(公告)号:US20220347094A1
公开(公告)日:2022-11-03
申请号:US17744189
申请日:2022-05-13
Applicant: Ocular Therapeutix, Inc.
Inventor: Charles D. Blizzard , Arthur Driscoll , Rami El-Hayek , Michael Goldstein , Joseph Iacona , Peter Jarrett , Timothy S. Jarrett , Erica Kahn , Zachary Lattrell
IPC: A61K9/00 , A61K9/06 , A61K31/4439 , A61K47/34 , A61P27/02 , A61K31/4427
Abstract: The invention relates to a sustained release biodegradable ocular implant containing a tyrosine kinase inhibitor dispersed in a hydrogel for the treatment of a retinal disease for an extended period of time.
-
公开(公告)号:US20220218643A1
公开(公告)日:2022-07-14
申请号:US17673265
申请日:2022-02-16
Applicant: OCULAR THERAPEUTIX, INC.
Inventor: Charles D. Blizzard , Ankita Desai , Arthur Driscoll , Michael Goldstein
IPC: A61K31/216 , A61P27/06 , A61K9/00 , A61K47/69 , A61K47/10
Abstract: The present invention relates to the treatment of ocular diseases in a human subject In particular, the invention relates to an intracameral administration of a sustained release biodegradable intracameral implant.
-
25.
公开(公告)号:US20220087932A1
公开(公告)日:2022-03-24
申请号:US17483250
申请日:2021-09-23
Applicant: Ocular Therapeutix, Inc.
Inventor: Charles D. Blizzard , Rami El-Hayek , Michael Goldstein , Peter Jarrett , Andrew Vanslette
Abstract: Provided herein are sustained release biodegradable intracanalicular insert comprising a hydrogel and cyclosporine, methods of treating or preventing an ocular disease in a subject in need thereof by administering such inserts as well as methods of manufacturing such inserts.
-
26.
公开(公告)号:US20220087931A1
公开(公告)日:2022-03-24
申请号:US17483220
申请日:2021-09-23
Applicant: Ocular Therapeutix, Inc.
Inventor: Charles D. Blizzard , Rami El-Hayek , Michael Goldstein , Peter Jarrett , Andrew Vanslette
Abstract: Provided herein are sustained release biodegradable intracanalicular insert comprising a hydrogel and cyclosporine, methods of treating or preventing an ocular disease in a subject in need thereof by administering such inserts as well as methods of manufacturing such inserts.
-
公开(公告)号:US20220079876A1
公开(公告)日:2022-03-17
申请号:US17210719
申请日:2021-03-24
Applicant: Ocular Therapeutix, Inc.
Inventor: Charles D. Blizzard , Arthur Driscoll , Rami El-Hayek , Michael Goldstein , Joseph Iacona , Peter Jarrett , Timothy S. Jarrett , Erica Kahn , Zachary Lattrell
IPC: A61K9/00 , A61K31/4427 , A61P27/02
Abstract: The invention relates to a sustained release biodegradable ocular implant containing a tyrosine kinase inhibitor dispersed in a hydrogel for the treatment of a retinal disease for an extended period of time.
-
公开(公告)号:US20210251893A1
公开(公告)日:2021-08-19
申请号:US17169020
申请日:2021-02-05
Applicant: Ocular Therapeutix, Inc.
Inventor: Charles D. Blizzard , Ankita Desai , Arthur Driscoll , Michael Goldstein
IPC: A61K9/00 , A61K31/5575 , A61K9/14 , C08L67/04
Abstract: The present invention relates to the treatment of ocular diseases in a human subject. In particular, the invention relates to an intracameral administration of a sustained release biodegradable intracameral implant.
-
-
-
-
-
-
-